New Launch26 Aug 2025, 09:42 am
Aurobindo Pharma Subsidiary Receives Approval for Trastuzumab Biosimilar Dazublys in UK
AI Summary
Aurobindo Pharma Ltd. has announced that its wholly owned step-down subsidiary, CuraTeQ Biologics s.r.o, has received approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its trastuzumab biosimilar version, Dazublys™. This marks the fourth biosimilar approval by MHRA for CuraTeQ, following Bevgolva™, Zefylti™, and Dyrupeg™. Dazublys™, Zefylti™, and Dyrupeg™ are also approved in the European Union.
Key Highlights
- Aurobindo Pharma's subsidiary, CuraTeQ Biologics s.r.o, received approval from UK's MHRA for Dazublys™, a trastuzumab biosimilar version.
- This is the fourth biosimilar approval by MHRA for CuraTeQ, following Bevgolva™, Zefylti™, and Dyrupeg™.
- Dazublys™, Zefylti™, and Dyrupeg™ are also approved in the European Union.
- Aurobindo Pharma continues to expand its biosimilar portfolio.
- The company is committed to providing high-quality, affordable biosimilar options to patients.